Designing of a Chimeric Vaccine Using EIS (Rv2416c) Protein Against Mycobacterium tuberculosis H37Rv: an Immunoinformatics Approach
Appl Biochem Biotechnol. 2021 Nov 24. doi: 10.1007/s12010-021-03760-0. Online ahead of print.ABSTRACTMycobacterium tuberculosis (Mtb) is a respiratory pathogen that causes tuberculosis (TB). There are a large number of proteins that are involved in the pathogenesis of TB. Stimulating the immune response against TB is very important to clear the pathogens from host. In the present study, an immunoinformatics conduit is used for designing an epitope based chimeric vaccine against TB. Enhanced intracellular survival (EIS) protein from Mtb is used for designing the chimeric vaccine. One B cell epitope, 8 cytotoxic T lymphocyte (CTL), and 6 helper T lymphocyte (HTL) epitopes were predicted based on the MHC allele binding, immunogenicity, antigenicity, allergenicity, toxicity and IFN epitopes. The selected epitopes were used for chimeric vaccine designing. Furthermore, 3D structure elucidation, structural refinement and validation of the designed chimeric vaccine were carried out. The 3D structure was used for protein-protein docking studies with Toll-like receptor 4 (TLR-4), followed by molecular dynamic simulation (MDS) and the interaction between the chimeric vaccine and TLR-4 complex was verified.PMID:34817805 | DOI:10.1007/s12010-021-03760-0
Source: Applied Biochemistry and Biotechnology - Category: Biochemistry Authors: R Logesh V Lavanya Shazia Jamal Neesar Ahmed Source Type: research
More News: Biochemistry | Biotechnology | Respiratory Medicine | Study | Toxicology | Tuberculosis | Vaccines